Understanding Postpartum Mental Health Problems

Postpartum mental health problems can range from mild ‘baby-blues’ to severe puerperal psychosis. To screen for depression, healthcare professionals may use the Edinburgh Postnatal Depression Scale, which is a 10-item questionnaire that indicates how the mother has felt over the previous week. A score of more than 13 indicates a ‘depressive illness of varying severity’, with sensitivity and specificity of more than 90%. The questionnaire also includes a question about self-harm.

‘Baby-blues’ is seen in around 60-70% of women and typically occurs 3-7 days following birth. It is more common in primips, and mothers are characteristically anxious, tearful, and irritable. Reassurance and support from healthcare professionals, particularly health visitors, play a key role in managing this condition. Most women with the baby blues will not require specific treatment other than reassurance.

Postnatal depression affects around 10% of women, with most cases starting within a month and typically peaking at 3 months. The features are similar to depression seen in other circumstances, and cognitive behavioural therapy may be beneficial. Certain SSRIs such as sertraline and paroxetine may be used if symptoms are severe. Although these medications are secreted in breast milk, they are not thought to be harmful to the infant.

Puerperal psychosis affects approximately 0.2% of women and requires admission to hospital, ideally in a Mother & Baby Unit. Onset usually occurs within the first 2-3 weeks following birth, and features include severe swings in mood (similar to bipolar disorder) and disordered perception (e.g. auditory hallucinations). There is around a 25-50% risk of recurrence following future pregnancies. Paroxetine is recommended by SIGN because of the low milk/plasma ratio, while fluoxetine is best avoided due to a long half-life.

Severe restlessness may be caused by antipsychotics, known as akathisia.

Antipsychotics are a group of drugs used to treat schizophrenia, psychosis, mania, and agitation. They are divided into two categories: typical and atypical antipsychotics. The latter were developed to address the extrapyramidal side-effects associated with the first generation of typical antipsychotics. Typical antipsychotics work by blocking dopaminergic transmission in the mesolimbic pathways through dopamine D2 receptor antagonism. They are associated with extrapyramidal side-effects and hyperprolactinaemia, which are less common with atypical antipsychotics.

Extrapyramidal side-effects (EPSEs) are common with typical antipsychotics and include Parkinsonism, acute dystonia, sustained muscle contraction, akathisia, and tardive dyskinesia. The latter is a late onset of choreoathetoid movements that may be irreversible and occur in 40% of patients. The Medicines and Healthcare products Regulatory Agency has issued specific warnings when antipsychotics are used in elderly patients, including an increased risk of stroke and venous thromboembolism. Other side-effects include antimuscarinic effects, sedation, weight gain, raised prolactin, impaired glucose tolerance, neuroleptic malignant syndrome, reduced seizure threshold, and prolonged QT interval.

Monitoring FBC is crucial in patients taking clozapine as agranulocytosis/neutropenia, a potentially fatal side effect, can occur. It is imperative to rule out neutropenia in case of infections.

Atypical antipsychotics are now recommended as the first-line treatment for patients with schizophrenia, as per the 2005 NICE guidelines. These medications have the advantage of significantly reducing extrapyramidal side-effects. However, they can also cause adverse effects such as weight gain, hyperprolactinaemia, and in the case of clozapine, agranulocytosis. The Medicines and Healthcare products Regulatory Agency has issued warnings about the increased risk of stroke and venous thromboembolism when antipsychotics are used in elderly patients. Examples of atypical antipsychotics include clozapine, olanzapine, risperidone, quetiapine, amisulpride, and aripiprazole.

Clozapine, one of the first atypical antipsychotics, carries a significant risk of agranulocytosis and requires full blood count monitoring during treatment. Therefore, it should only be used in patients who are resistant to other antipsychotic medication. The BNF recommends introducing clozapine if schizophrenia is not controlled despite the sequential use of two or more antipsychotic drugs, one of which should be a second-generation antipsychotic drug, each for at least 6-8 weeks. Adverse effects of clozapine include agranulocytosis, neutropaenia, reduced seizure threshold, constipation, myocarditis, and hypersalivation. Dose adjustment of clozapine may be necessary if smoking is started or stopped during treatment.

Understanding the Difference between Hypomania and Mania

Hypomania and mania are two terms that are often used interchangeably, but they actually refer to two different conditions. While both conditions share some common symptoms, there are some key differences that set them apart.

Mania is a more severe form of hypomania that lasts for at least seven days and can cause significant impairment in social and work settings. It may require hospitalization due to the risk of harm to oneself or others and may present with psychotic symptoms such as delusions of grandeur or auditory hallucinations.

On the other hand, hypomania is a lesser version of mania that lasts for less than seven days, typically 3-4 days. It does not impair functional capacity in social or work settings and is unlikely to require hospitalization. It also does not exhibit any psychotic symptoms.

Both hypomania and mania share common symptoms such as elevated or irritable mood, pressured speech, flight of ideas, poor attention, insomnia, loss of inhibitions, increased appetite, and risk-taking behavior. However, the length of symptoms, severity, and presence of psychotic symptoms help differentiate mania from hypomania.

Benzodiazepines are drugs that enhance the effect of the neurotransmitter GABA, which inhibits brain activity. They are used for various purposes, including sedation, anxiety relief, muscle relaxation, and seizure prevention. However, patients can develop a tolerance and dependence on these drugs, so they should only be prescribed for a short period of time. When withdrawing from benzodiazepines, it is important to do so gradually to avoid withdrawal symptoms, which can include insomnia, anxiety, and seizures. Barbiturates are another type of drug that affect GABA, but they work differently than benzodiazepines by increasing the duration of chloride channel opening.

For patients with moderate-severe depression, subthreshold depressive symptoms that have persisted for a long period, subthreshold symptoms or mild depression that persists after other interventions, or mild depression that is complicating the care of a chronic physical health problem, antidepressants are recommended. The first-line antidepressant recommended by NICE is selective serotonin reuptake inhibitors (SSRIs), such as citalopram, fluoxetine, paroxetine, and sertraline. Tricyclic antidepressants (TCAs), such as amitriptyline, should be avoided as first-line or if there is a history or likelihood of overdose due to their high toxicity in overdose.

In 2022, NICE updated its guidelines on managing depression and now classifies it as either less severe or more severe based on a patient’s PHQ-9 score. For less severe depression, NICE recommends discussing treatment options with patients and considering the least intrusive and resource-intensive treatment first. Antidepressant medication should not be routinely offered as first-line treatment unless it is the patient’s preference. Treatment options for less severe depression include guided self-help, group cognitive behavioral therapy, group behavioral activation, individual CBT or BA, group exercise, group mindfulness and meditation, interpersonal psychotherapy, SSRIs, counseling, and short-term psychodynamic psychotherapy. For more severe depression, NICE recommends a shared decision-making approach and suggests a combination of individual CBT and an antidepressant as the preferred treatment option. Other treatment options for more severe depression include individual CBT or BA, antidepressant medication, individual problem-solving, counseling, short-term psychodynamic psychotherapy, interpersonal psychotherapy, guided self-help, and group exercise.

If a person dies while under the mental health act, regardless of the cause of death, it is mandatory to report their death to the coroner. In this case, as the individual was detained under the mental health act at the time of their death, it is the responsibility of the doctors in the hospital where they passed away to issue the MCCD after discussing with the coroner. It would be inappropriate to ask the GP who performed their surgery over a year ago to issue the MCCD as they may not have seen the individual within 14 days prior to their death. Additionally, the doctors at the psychiatric hospital may have seen the individual within the 14 days prior, but it is still the responsibility of the hospital doctors who were caring for them at the time of their death to issue the MCCD.

Sectioning under the Mental Health Act is a legal process used for individuals who refuse voluntary admission. This process excludes patients who are under the influence of drugs or alcohol. There are several sections under the Mental Health Act that allow for different types of admission and treatment.

Section 2 allows for admission for assessment for up to 28 days, which is not renewable. An Approved Mental Health Professional (AMHP) or the nearest relative (NR) can make the application on the recommendation of two doctors, one of whom should be an approved consultant psychiatrist. Treatment can be given against the patient’s wishes.

Section 3 allows for admission for treatment for up to 6 months, which can be renewed. An AMHP and two doctors, both of whom must have seen the patient within the past 24 hours, can make the application. Treatment can also be given against the patient’s wishes.

Section 4 is used as an emergency 72-hour assessment order when a section 2 would involve an unacceptable delay. A GP and an AMHP or NR can make the application, which is often changed to a section 2 upon arrival at the hospital.

Section 5(2) allows a doctor to legally detain a voluntary patient in hospital for 72 hours, while section 5(4) allows a nurse to detain a voluntary patient for 6 hours.

Section 17a allows for Supervised Community Treatment (Community Treatment Order) and can be used to recall a patient to the hospital for treatment if they do not comply with the conditions of the order in the community, such as taking medication.

Section 135 allows for a court order to be obtained to allow the police to break into a property to remove a person to a Place of Safety. Section 136 allows for someone found in a public place who appears to have a mental disorder to be taken by the police to a Place of Safety. This section can only be used for up to 24 hours while a Mental Health Act assessment is arranged.

Differential Diagnosis: Jaundice and Abdominal Symptoms

Gilbert Syndrome:
Gilbert syndrome is an inherited condition that can manifest as jaundice on clinical examination. Patients may also experience non-specific symptoms such as abdominal cramps, fatigue, and malaise. Fasting, febrile illness, alcohol, or exercise can exacerbate jaundice in patients with Gilbert syndrome. Diagnosis is based on a thorough history and physical examination, as well as blood tests that show unconjugated hyperbilirubinaemia.

Haemolytic Anaemia:
Haemolysis is the premature destruction of erythrocytes, which can lead to anaemia if bone marrow activity cannot compensate for erythrocyte loss. Mild haemolysis can be asymptomatic, while severe haemolysis can cause life-threatening symptoms such as angina and cardiopulmonary decompensation. Changes in lactate dehydrogenase and serum haptoglobin levels are the most sensitive general tests for haemolytic anaemia.

Hepatitis A:
Hepatitis A is a viral infection that results almost exclusively from ingestion, typically through faecal-oral transmission. Symptoms include fatigue, anorexia, nausea, and vomiting. LFT abnormalities are common, and diagnosis is based on serologic testing for immunoglobulin M (IgM) antibody to HAV.

Hepatitis B:
Hepatitis B is a viral infection that is transmitted haematogenously and sexually. Symptoms include fatigue, anorexia, nausea, and vomiting. LFT abnormalities are common, and diagnosis is based on serologic testing for hepatitis B surface antigen (HBsAg).

Cholecystitis:
Cholecystitis is inflammation of the gall bladder that occurs most commonly because of an obstruction of the cystic duct by gallstones arising from the gall bladder. Symptoms include upper abdominal pain, nausea, vomiting, and fever. Signs of peritoneal irritation may also be present.

Conclusion:
In summary, the differential diagnosis of jaundice and abdominal symptoms includes Gilbert syndrome, haemolytic anaemia, hepatitis A, hepatitis B, and cholecystitis. Diagnosis is based on a thorough history and physical examination, as well as blood tests and serologic testing as appropriate. Treatment

Overflow incontinence can be caused by tricyclic antidepressants due to their anticholinergic effects.

The drug class of tricyclic antidepressants, which includes Amitriptyline, can lead to urinary retention and frequent leaking due to their anticholinergic effects. Antimuscarinic drugs can be used to treat urge incontinence, which is caused by detrusor over-activity, while stress incontinence, which occurs when the bladder is under pressure, can result in urine leakage when coughing or laughing.

Tricyclic Antidepressants for Neuropathic Pain

Tricyclic antidepressants (TCAs) were once commonly used for depression, but their side-effects and toxicity in overdose have led to a decrease in their use. However, they are still widely used in the treatment of neuropathic pain, where smaller doses are typically required. TCAs such as low-dose amitriptyline are commonly used for the management of neuropathic pain and the prophylaxis of headache, while lofepramine has a lower incidence of toxicity in overdose. It is important to note that some TCAs, such as amitriptyline and dosulepin, are considered more dangerous in overdose than others.

Common side-effects of TCAs include drowsiness, dry mouth, blurred vision, constipation, urinary retention, and lengthening of the QT interval. When choosing a TCA for neuropathic pain, the level of sedation may also be a consideration. Amitriptyline, clomipramine, dosulepin, and trazodone are more sedative, while imipramine, lofepramine, and nortriptyline are less sedative. It is important to work with a healthcare provider to determine the appropriate TCA and dosage for the individual’s specific needs.

Alcohol withdrawal occurs due to a decrease in the inhibitory neurotransmitter GABA and an increase in the excitatory neurotransmitter NMDA glutamate. GABA typically reduces brain activity and induces a calming effect when levels are high, which is heightened during alcohol consumption. On the other hand, glutamate increases brain activity and acts as a natural stimulant, which is reduced during alcohol consumption, leading to a physiological slowdown.

When a person drinks alcohol, the brain assumes that there is an excess of GABA and a shortage of glutamate. However, if the person continues to drink excessively, the brain produces less GABA and more glutamate to restore normal brain chemistry. If the person then stops drinking, the brain experiences a rebound effect, where it still produces less GABA and more glutamate than required without alcohol. As a result, the brain acts as if there is a deficiency of GABA and an excess of glutamate, leading to withdrawal symptoms.

Alcohol withdrawal occurs when an individual who has been consuming alcohol chronically suddenly stops or reduces their intake. Chronic alcohol consumption enhances the inhibitory effects of GABA in the central nervous system, similar to benzodiazepines, and inhibits NMDA-type glutamate receptors. However, alcohol withdrawal leads to the opposite effect, resulting in decreased inhibitory GABA and increased NMDA glutamate transmission. Symptoms of alcohol withdrawal typically start at 6-12 hours and include tremors, sweating, tachycardia, and anxiety. Seizures are most likely to occur at 36 hours, while delirium tremens, which includes coarse tremors, confusion, delusions, auditory and visual hallucinations, fever, and tachycardia, peak at 48-72 hours.

Patients with a history of complex withdrawals from alcohol, such as delirium tremens, seizures, or blackouts, should be admitted to the hospital for monitoring until their withdrawals stabilize. The first-line treatment for alcohol withdrawal is long-acting benzodiazepines, such as chlordiazepoxide or diazepam, which are typically given as part of a reducing dose protocol. Lorazepam may be preferable in patients with hepatic failure. Carbamazepine is also effective in treating alcohol withdrawal, while phenytoin is said to be less effective in treating alcohol withdrawal seizures.

The woman is exhibiting clear indications of a manic episode, including rapid speech, uninhibited behavior, and grandiose delusions. Tests for drugs and alcohol have ruled out intoxication or drug-induced psychosis. Schizophrenia is unlikely as a first-time diagnosis, and the symptoms suggest mania or bipolar disorder. However, a diagnosis of bipolar disorder cannot be made without evidence of depressive symptoms. Therefore, the correct diagnosis in this case is an isolated manic episode of unknown origin.

Understanding the Difference between Hypomania and Mania

Hypomania and mania are two terms that are often used interchangeably, but they actually refer to two different conditions. While both conditions share some common symptoms, there are some key differences that set them apart.

Mania is a more severe form of hypomania that lasts for at least seven days and can cause significant impairment in social and work settings. It may require hospitalization due to the risk of harm to oneself or others and may present with psychotic symptoms such as delusions of grandeur or auditory hallucinations.

On the other hand, hypomania is a lesser version of mania that lasts for less than seven days, typically 3-4 days. It does not impair functional capacity in social or work settings and is unlikely to require hospitalization. It also does not exhibit any psychotic symptoms.

Both hypomania and mania share common symptoms such as elevated or irritable mood, pressured speech, flight of ideas, poor attention, insomnia, loss of inhibitions, increased appetite, and risk-taking behavior. However, the length of symptoms, severity, and presence of psychotic symptoms help differentiate mania from hypomania.

Understanding Schizoid Personality Disorder: Differentiating from Other Psychiatric Conditions

Personality disorders are characterized by enduring patterns of perception, processing, and engagement that become ingrained, inflexible, and maladaptive. Schizoid personality disorder is a type of personality disorder that falls under the weird cluster of disorders. Patients with this disorder are withdrawn loners with flat affects, but they do not have weird/magical thinking (schizotypal) or psychotic symptoms (schizophrenia, schizoaffective disorder). They classically have a very flat affect and no interest in interpersonal relationships, preferring to work and play alone. It is important to differentiate schizoid personality disorder from other psychiatric conditions such as schizophrenia, avoidant personality disorder, schizoaffective disorder, and schizotypal personality disorder, as they have distinct features and treatment approaches.

The most likely diagnosis for the patient in this vignette is schizophrenia. Early symptoms of schizophrenia can include social withdrawal and behavioral changes, which may go unnoticed before the onset of delusions and hallucinations. The patient’s belief that his mother is trying to poison him needs to be explored to confirm whether it is an actual delusion. While illicit drug use can cause psychotic symptoms similar to schizophrenia, the gradual onset and progression of symptoms in this case suggest a diagnosis of schizophrenia rather than amphetamine misuse. Depression can also cause delusions, but depressive delusions are usually congruent with the mood and tend to have themes of guilt or hopelessness. The combination of symptoms presented in this vignette cannot be safely explained by normal teenage behavior. While schizotypal disorder can resemble schizophrenia, it does not have the characteristic symptoms seen in this vignette.

Selective serotonin reuptake inhibitors (SSRIs) are commonly used as the first-line treatment for depression. Citalopram and fluoxetine are the preferred SSRIs, while sertraline is recommended for patients who have had a myocardial infarction. However, caution should be exercised when prescribing SSRIs to children and adolescents. Gastrointestinal symptoms are the most common side-effect, and patients taking SSRIs are at an increased risk of gastrointestinal bleeding. Patients should also be aware of the possibility of increased anxiety and agitation after starting a SSRI. Fluoxetine and paroxetine have a higher propensity for drug interactions.

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a warning regarding the use of citalopram due to its association with dose-dependent QT interval prolongation. As a result, citalopram and escitalopram should not be used in patients with congenital long QT syndrome, known pre-existing QT interval prolongation, or in combination with other medicines that prolong the QT interval. The maximum daily dose of citalopram is now 40 mg for adults, 20 mg for patients older than 65 years, and 20 mg for those with hepatic impairment.

When initiating antidepressant therapy, patients should be reviewed by a doctor after 2 weeks. Patients under the age of 25 years or at an increased risk of suicide should be reviewed after 1 week. If a patient responds well to antidepressant therapy, they should continue treatment for at least 6 months after remission to reduce the risk of relapse. When stopping a SSRI, the dose should be gradually reduced over a 4 week period, except for fluoxetine. Paroxetine has a higher incidence of discontinuation symptoms, including mood changes, restlessness, difficulty sleeping, unsteadiness, sweating, gastrointestinal symptoms, and paraesthesia.

When considering the use of SSRIs during pregnancy, the benefits and risks should be weighed. Use during the first trimester may increase the risk of congenital heart defects, while use during the third trimester can result in persistent pulmonary hypertension of the newborn. Paroxetine has an increased risk of congenital malformations, particularly in the first trimester.

Understanding the Risk Factors for Suicide

Suicide is a complex issue with a variety of risk factors. The strongest indicators of suicide are the presence of a mental disorder, including alcohol-use disorder, and a history of previous suicide attempts. Age and sex also play a role, with the risk increasing with age and men being more likely to complete suicide. Marital status, unemployment, living alone, and chronic illnesses are also associated with an increased risk. It is important to understand these risk factors in order to identify and prevent suicide.

Patients who are taking warfarin or heparin should avoid taking selective serotonin reuptake inhibitors (SSRIs) due to their antiplatelet effect, which can increase the risk of bleeding. Therefore, citalopram is the appropriate choice. It is important to note that some tricyclic antidepressants and mirtazapine can also increase the INR, so caution is necessary when prescribing these medications. According to the Nice CKS guidelines on warfarin administration, trazodone may be the preferred antidepressant for these patients.

Selective serotonin reuptake inhibitors (SSRIs) are commonly used as the first-line treatment for depression. Citalopram and fluoxetine are the preferred SSRIs, while sertraline is recommended for patients who have had a myocardial infarction. However, caution should be exercised when prescribing SSRIs to children and adolescents. Gastrointestinal symptoms are the most common side-effect, and patients taking SSRIs are at an increased risk of gastrointestinal bleeding. Patients should also be aware of the possibility of increased anxiety and agitation after starting a SSRI. Fluoxetine and paroxetine have a higher propensity for drug interactions.

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a warning regarding the use of citalopram due to its association with dose-dependent QT interval prolongation. As a result, citalopram and escitalopram should not be used in patients with congenital long QT syndrome, known pre-existing QT interval prolongation, or in combination with other medicines that prolong the QT interval. The maximum daily dose of citalopram is now 40 mg for adults, 20 mg for patients older than 65 years, and 20 mg for those with hepatic impairment.

When initiating antidepressant therapy, patients should be reviewed by a doctor after 2 weeks. Patients under the age of 25 years or at an increased risk of suicide should be reviewed after 1 week. If a patient responds well to antidepressant therapy, they should continue treatment for at least 6 months after remission to reduce the risk of relapse. When stopping a SSRI, the dose should be gradually reduced over a 4 week period, except for fluoxetine. Paroxetine has a higher incidence of discontinuation symptoms, including mood changes, restlessness, difficulty sleeping, unsteadiness, sweating, gastrointestinal symptoms, and paraesthesia.

When considering the use of SSRIs during pregnancy, the benefits and risks should be weighed. Use during the first trimester may increase the risk of congenital heart defects, while use during the third trimester can result in persistent pulmonary hypertension of the newborn. Paroxetine has an increased risk of congenital malformations, particularly in the first trimester.

The Use of Varenicline in Smoking Cessation and Other Substance Withdrawals

Varenicline, marketed as Champix®, is a medication used in combination with motivational support to aid smoking cessation. The National Institute for Health and Care Excellence (NICE) recommends offering varenicline or nicotine replacement therapy (NRT) to all smokers, along with advice and encouragement to quit. The choice of therapy depends on factors such as the smoker’s compliance, availability of counseling and support, previous experience with cessation aids, contraindications, and personal preference. However, varenicline use has been associated with changes in behavior and thinking, anxiety, psychosis, mood swings, depression, and suicidal ideation, so monitoring is advised.

While varenicline is not currently indicated for cannabis cessation, some studies suggest that it may reduce the enjoyment reported from using cannabis, which could lead to further investigation in this area. However, varenicline has no role in the treatment of alcohol withdrawal, and the FDA has warned that people taking varenicline should reduce their alcohol intake due to the potential for unusual behavior, including aggression. The use of varenicline for opioid withdrawal in patients with chronic pain is also under investigation but is not currently recommended. Finally, varenicline is not indicated for cocaine cessation.

Schizophrenia that is resistant to treatment can be very challenging to manage. Clozapine, an atypical antipsychotic, is one of the most effective drugs for this condition. However, it should only be used as a second or third line medication after trying at least two other antipsychotics for 6-8 weeks, with one of them being from the atypical class. Although clozapine is highly effective, it can cause serious side effects such as weight gain, excessive salivation, agranulocytosis, neutropenia, myocarditis, and arrhythmias. In this patient’s case, there is concern that he may be experiencing myocarditis due to his underlying psychiatric condition and potential use of clozapine.

Management of Schizophrenia: NICE Guidelines

Schizophrenia is a complex mental disorder that requires careful management. In 2009, the National Institute for Health and Care Excellence (NICE) published guidelines on the management of schizophrenia. According to these guidelines, oral atypical antipsychotics should be the first-line treatment for patients with schizophrenia. Additionally, cognitive behavioural therapy should be offered to all patients to help them manage their symptoms and improve their quality of life.

It is also important to pay close attention to cardiovascular risk-factor modification in patients with schizophrenia. This is because schizophrenic patients have high rates of cardiovascular disease, which is linked to antipsychotic medication and high smoking rates. Therefore, healthcare providers should work with patients to modify their lifestyle habits and reduce their risk of developing cardiovascular disease.

Overall, the NICE guidelines provide a comprehensive approach to managing schizophrenia. By following these guidelines, healthcare providers can help patients with schizophrenia achieve better outcomes and improve their overall health and well-being.

Duration of Antidepressant Treatment for Depression

It is recommended that a single episode of depression should be treated for at least six months after recovery to prevent relapse. Recurrent episodes warrant at least 12 months of treatment after recovery. Stopping antidepressant treatment immediately on recovery puts patients at a high risk of relapse, with 50% of patients experiencing a relapse of their depressive symptoms. During the recovery phase, adults should receive the same dose used for the treatment of the acute phase. The medication should then be tapered off over a few weeks, according to the type of antidepressant used.

Stopping medication prematurely, such as after one month or six weeks, would put the patient at a high risk of relapse. If the patient has been using antidepressants over a very short term and has found it maximally effective, they may be able to come off medication sooner than six months. However, this should be managed with caution and only recommended if there are other extenuating factors which would cause them to want to stop, such as side-effects or poor compliance. In this case, the patient has been using sertraline for four months already, has not indicated poor compliance, and there is no indication of issues with side-effects.

Arm cutting may be seen as attention-seeking or a way to release pain, but studies indicate that it increases the risk of suicide for those with a history of deliberate self harm. Employment is a protective factor.

Suicide Risk Factors and Protective Factors

Suicide risk assessment is a common practice in psychiatric care, with patients being stratified into high, medium, or low risk categories. However, there is a lack of evidence on the positive predictive value of individual risk factors. A review in the BMJ concluded that such assessments may not be useful in guiding decision-making, as 50% of suicides occur in patients deemed low risk. Nevertheless, certain factors have been associated with an increased risk of suicide, including male sex, history of deliberate self-harm, alcohol or drug misuse, mental illness, depression, schizophrenia, chronic disease, advancing age, unemployment or social isolation, and being unmarried, divorced, or widowed.

If a patient has attempted suicide, there are additional risk factors to consider, such as efforts to avoid discovery, planning, leaving a written note, final acts such as sorting out finances, and using a violent method. On the other hand, there are protective factors that can reduce the risk of suicide, such as family support, having children at home, and religious belief. It is important to consider both risk and protective factors when assessing suicide risk and developing a treatment plan.

Weight gain is a common side effect of atypical antipsychotics.

Atypical antipsychotics are now recommended as the first-line treatment for patients with schizophrenia, as per the 2005 NICE guidelines. These medications have the advantage of significantly reducing extrapyramidal side-effects. However, they can also cause adverse effects such as weight gain, hyperprolactinaemia, and in the case of clozapine, agranulocytosis. The Medicines and Healthcare products Regulatory Agency has issued warnings about the increased risk of stroke and venous thromboembolism when antipsychotics are used in elderly patients. Examples of atypical antipsychotics include clozapine, olanzapine, risperidone, quetiapine, amisulpride, and aripiprazole.

Clozapine, one of the first atypical antipsychotics, carries a significant risk of agranulocytosis and requires full blood count monitoring during treatment. Therefore, it should only be used in patients who are resistant to other antipsychotic medication. The BNF recommends introducing clozapine if schizophrenia is not controlled despite the sequential use of two or more antipsychotic drugs, one of which should be a second-generation antipsychotic drug, each for at least 6-8 weeks. Adverse effects of clozapine include agranulocytosis, neutropaenia, reduced seizure threshold, constipation, myocarditis, and hypersalivation. Dose adjustment of clozapine may be necessary if smoking is started or stopped during treatment.

Differentiating between Mental Disorders: Tourette’s Syndrome, Malingering, Conduct Disorder, Dissocial Personality Disorder, and Schizophrenia

Tourette’s Syndrome is a tic disorder that usually develops in childhood or adolescence, characterized by multiple motor tics and one or more vocal tics. The vocal tics need not be complete words or phrases and are often throat-clearing and grunting. Anti-psychotics such as pimozide, risperidone, and sulpiride have been shown to be of benefit.

Malingering is the act of fabricating symptoms for some sort of secondary gain, such as financial, manipulative, avoidance of school, obtaining drugs, or gaining sympathy or attention.

Conduct Disorder is a mental disorder diagnosed before or after the age of 10, characterized by a persistent and repetitive pattern of behavior that violates either the basic rights of others or goes against age-developmental norms. Childhood onset disorder can be linked to attention deficit/hyperactivity disorder (ADHD) type symptoms.

Dissocial Personality Disorder is characterized by a long-term disregard for others or the violation of others. Its precursor is conduct disorder. Antisocial personality disorder can be diagnosed when the patient reaches the age of 18 and has a history of conduct disorder in childhood or adolescence.

Schizophrenia does not typically present with involuntary movements. There is also no history of hallucinations, auditory or visual, or confused thinking.

The young man in question is likely suffering from borderline personality disorder (BPD), also known as emotionally unstable personality disorder (EUPD). This condition is characterized by unstable relationships, alternating between idealization and devaluation of others, recurrent self-harm, unstable self-image and self-esteem, suicidal behavior, difficulty controlling anger, and efforts to avoid abandonment. All of these traits are present in this patient, making BPD the most likely diagnosis.

Narcissistic personality disorder is not a likely diagnosis for this patient, as it is characterized by a grandiose sense of self-importance, lack of empathy, and a sense of entitlement. These traits are not present in this patient, and his periods of devaluing her partner are temporary and not pervasive.

Dependent personality disorder is also an unlikely diagnosis, as this condition is characterized by a pervasive need for others to make decisions for the patient and constant reassurance. While the patient has felt that he cannot live without his partner in the past, his labile mood and alternating view of his partner make this diagnosis less likely.

Paranoid personality disorder is also an unlikely diagnosis, as patients with this condition tend to be reluctant to confide in others and have an unforgiving attitude when insulted or questioned. The patient in question does not exhibit these traits, and his difficulty with trusting friends is likely due to his belief that he is undeserving of them.

Personality disorders are a set of personality traits that are maladaptive and interfere with normal functioning in life. It is estimated that around 1 in 20 people have a personality disorder, which are typically categorized into three clusters: Cluster A, which includes Odd or Eccentric disorders such as Paranoid, Schizoid, and Schizotypal; Cluster B, which includes Dramatic, Emotional, or Erratic disorders such as Antisocial, Borderline (Emotionally Unstable), Histrionic, and Narcissistic; and Cluster C, which includes Anxious and Fearful disorders such as Obsessive-Compulsive, Avoidant, and Dependent.

Paranoid individuals exhibit hypersensitivity and an unforgiving attitude when insulted, a reluctance to confide in others, and a preoccupation with conspirational beliefs and hidden meanings. Schizoid individuals show indifference to praise and criticism, a preference for solitary activities, and emotional coldness. Schizotypal individuals exhibit odd beliefs and magical thinking, unusual perceptual disturbances, and inappropriate affect. Antisocial individuals fail to conform to social norms, deceive others, and exhibit impulsiveness, irritability, and aggressiveness. Borderline individuals exhibit unstable interpersonal relationships, impulsivity, and affective instability. Histrionic individuals exhibit inappropriate sexual seductiveness, a need to be the center of attention, and self-dramatization. Narcissistic individuals exhibit a grandiose sense of self-importance, lack of empathy, and excessive need for admiration. Obsessive-compulsive individuals are occupied with details, rules, and organization to the point of hampering completion of tasks. Avoidant individuals avoid interpersonal contact due to fears of criticism or rejection, while dependent individuals have difficulty making decisions without excessive reassurance from others.

Personality disorders are difficult to treat, but a number of approaches have been shown to help patients, including psychological therapies such as dialectical behavior therapy and treatment of any coexisting psychiatric conditions.

Understanding Abnormal and Normal Grief Reactions

Grief is a highly individualized experience that can be influenced by personal, social, and cultural factors. There are three recognized types of abnormal grief reactions: delayed, inhibited, and prolonged. Delayed grief is characterized by a delay of more than two weeks before grieving begins, or sometimes not occurring at all until triggered by another subsequent bereavement. Inhibited grief occurs when the bereaved person appears minimally affected by the death, and prolonged grief lasts significantly longer than average.

On the other hand, normal grief reactions are characterized by features such as sadness, weeping, poor sleep, reduced appetite, motor restlessness, searching for the deceased, poor concentration and memory, low mood (but not frank depression), and the impression of seeing or hearing the deceased. Poor memory, brief episodes of seeing the dead person, poor concentration, and searching for the deceased are all common manifestations of a normal grief reaction.

It is important to note that there is a great degree of flexibility when assessing whether a grief reaction is normal or abnormal, as it is a highly personal experience. Understanding the different types of grief reactions can help individuals and their loved ones navigate the grieving process and seek appropriate support.

Understanding Movement Disorders Associated with Anti-Psychotic Medication

Anti-psychotic medication can cause a range of movement disorders, including tardive dyskinesia, akathisia, and Parkinsonism. Tardive dyskinesia is a common side-effect of long-term treatment with anti-psychotics, but can also occur with minimal doses. It is characterized by choreoathetoid movements, often starting in the fingers and tongue and becoming more generalized. Treatment is often unsuccessful, but may involve switching to a different medication or using agents such as tetrabenazine or benzodiazepines. Akathisia is an inner feeling of motor restlessness, with voluntary movements such as pacing or rocking. Parkinsonism is characterized by resting tremor, rigidity, and bradykinesia. These movement disorders can be mistaken for other conditions such as Huntington’s or Wilson’s disease, but the association with anti-psychotic medication and the specific symptoms make tardive dyskinesia a more likely option. It is important for healthcare professionals to monitor patients on anti-psychotic medication for these potential side-effects and adjust treatment as necessary.

If the police believe that someone requires a mental health assessment or treatment, they can request a section 135 to remove the individual from their property. The procedure involves an Approved Mental Health Practitioner (AMHP) presenting evidence at a Magistrate’s Court to obtain a warrant. This warrant permits the Police, an AMHP, and a registered medical practitioner to enter the premises and conduct an assessment or take the person to a safe location for evaluation.

Sectioning under the Mental Health Act is a legal process used for individuals who refuse voluntary admission. This process excludes patients who are under the influence of drugs or alcohol. There are several sections under the Mental Health Act that allow for different types of admission and treatment.

Section 2 allows for admission for assessment for up to 28 days, which is not renewable. An Approved Mental Health Professional (AMHP) or the nearest relative (NR) can make the application on the recommendation of two doctors, one of whom should be an approved consultant psychiatrist. Treatment can be given against the patient’s wishes.

Section 3 allows for admission for treatment for up to 6 months, which can be renewed. An AMHP and two doctors, both of whom must have seen the patient within the past 24 hours, can make the application. Treatment can also be given against the patient’s wishes.

Section 4 is used as an emergency 72-hour assessment order when a section 2 would involve an unacceptable delay. A GP and an AMHP or NR can make the application, which is often changed to a section 2 upon arrival at the hospital.

Section 5(2) allows a doctor to legally detain a voluntary patient in hospital for 72 hours, while section 5(4) allows a nurse to detain a voluntary patient for 6 hours.

Section 17a allows for Supervised Community Treatment (Community Treatment Order) and can be used to recall a patient to the hospital for treatment if they do not comply with the conditions of the order in the community, such as taking medication.

Section 135 allows for a court order to be obtained to allow the police to break into a property to remove a person to a Place of Safety. Section 136 allows for someone found in a public place who appears to have a mental disorder to be taken by the police to a Place of Safety. This section can only be used for up to 24 hours while a Mental Health Act assessment is arranged.

This scenario requires you to demonstrate your ability to evaluate and handle a patient who is contemplating suicide. The patient in question has several risk factors, including being male, having a history of depression, recently going through a separation, and expressing a desire to end his life in the future. It is crucial to respond appropriately in this situation. The most suitable team to evaluate and manage this patient is the CRISIS team, who can provide urgent assessment and care.

The other options are not as effective. Transferring the patient to the Emergency Department would only delay the referral to the crisis team. CAMH, which stands for child and adolescent mental health, is not the appropriate team to handle this case. It is not within your professional scope to initiate relationship counseling. Given the patient’s numerous risk factors, it would not be safe to discharge him without a psychiatric evaluation.

In 2022, NICE updated its guidelines on managing depression and now classifies it as either less severe or more severe based on a patient’s PHQ-9 score. For less severe depression, NICE recommends discussing treatment options with patients and considering the least intrusive and resource-intensive treatment first. Antidepressant medication should not be routinely offered as first-line treatment unless it is the patient’s preference. Treatment options for less severe depression include guided self-help, group cognitive behavioral therapy, group behavioral activation, individual CBT or BA, group exercise, group mindfulness and meditation, interpersonal psychotherapy, SSRIs, counseling, and short-term psychodynamic psychotherapy. For more severe depression, NICE recommends a shared decision-making approach and suggests a combination of individual CBT and an antidepressant as the preferred treatment option. Other treatment options for more severe depression include individual CBT or BA, antidepressant medication, individual problem-solving, counseling, short-term psychodynamic psychotherapy, interpersonal psychotherapy, guided self-help, and group exercise.

Antipsychotics have the potential to cause acute dystonic reactions, including oculogyric crises. Symptoms may also include jaw spasms and tongue protrusion. Treatment typically involves administering IV procyclidine and discontinuing the medication responsible for the reaction. Akathisia is another potential side effect, characterized by restlessness and an inability to sit still. Tardive dyskinesia is a long-term side effect that can develop after years of antipsychotic use, resulting in involuntary facial movements such as grimacing, tongue protrusion, and lip smacking. Parkinsonism is a term used to describe antipsychotic side effects that mimic Parkinson’s disease, such as bradykinesia, cogwheel rigidity, and a shuffling gait.

Antipsychotics are a group of drugs used to treat schizophrenia, psychosis, mania, and agitation. They are divided into two categories: typical and atypical antipsychotics. The latter were developed to address the extrapyramidal side-effects associated with the first generation of typical antipsychotics. Typical antipsychotics work by blocking dopaminergic transmission in the mesolimbic pathways through dopamine D2 receptor antagonism. They are associated with extrapyramidal side-effects and hyperprolactinaemia, which are less common with atypical antipsychotics.

Extrapyramidal side-effects (EPSEs) are common with typical antipsychotics and include Parkinsonism, acute dystonia, sustained muscle contraction, akathisia, and tardive dyskinesia. The latter is a late onset of choreoathetoid movements that may be irreversible and occur in 40% of patients. The Medicines and Healthcare products Regulatory Agency has issued specific warnings when antipsychotics are used in elderly patients, including an increased risk of stroke and venous thromboembolism. Other side-effects include antimuscarinic effects, sedation, weight gain, raised prolactin, impaired glucose tolerance, neuroleptic malignant syndrome, reduced seizure threshold, and prolonged QT interval.

The police can utilize Section 136 to transport individuals who may be exhibiting indications of mental illness and pose a danger to themselves or others to a secure location. This section is only valid for a maximum of 24 hours, during which time a Mental Health Act Assessment can be scheduled. In rare cases, it may be extended by an additional 12 hours. It is only applicable to individuals in public areas, not in their own or someone else’s residence – Section 135 is required for this. It does not authorize involuntary treatment. A secure location can be a hospital, the individual’s home or a friend’s home, or, if no other option is available, a police station.

Sectioning under the Mental Health Act is a legal process used for individuals who refuse voluntary admission. This process excludes patients who are under the influence of drugs or alcohol. There are several sections under the Mental Health Act that allow for different types of admission and treatment.

Section 2 allows for admission for assessment for up to 28 days, which is not renewable. An Approved Mental Health Professional (AMHP) or the nearest relative (NR) can make the application on the recommendation of two doctors, one of whom should be an approved consultant psychiatrist. Treatment can be given against the patient’s wishes.

Section 3 allows for admission for treatment for up to 6 months, which can be renewed. An AMHP and two doctors, both of whom must have seen the patient within the past 24 hours, can make the application. Treatment can also be given against the patient’s wishes.

Section 4 is used as an emergency 72-hour assessment order when a section 2 would involve an unacceptable delay. A GP and an AMHP or NR can make the application, which is often changed to a section 2 upon arrival at the hospital.

Section 5(2) allows a doctor to legally detain a voluntary patient in hospital for 72 hours, while section 5(4) allows a nurse to detain a voluntary patient for 6 hours.

Section 17a allows for Supervised Community Treatment (Community Treatment Order) and can be used to recall a patient to the hospital for treatment if they do not comply with the conditions of the order in the community, such as taking medication.

Section 135 allows for a court order to be obtained to allow the police to break into a property to remove a person to a Place of Safety. Section 136 allows for someone found in a public place who appears to have a mental disorder to be taken by the police to a Place of Safety. This section can only be used for up to 24 hours while a Mental Health Act assessment is arranged.

Features and Diagnostic Criteria of Anorexia Nervosa

Anorexia Nervosa (AN) is a serious eating disorder characterized by a distorted body image and an intense fear of gaining weight. Here are some features and diagnostic criteria of AN:

Increased excessive physical activity: Patients with AN tend to exercise excessively to lose weight.

Low plasma cortisol levels: AN patients have low levels of cortisol, a hormone that helps regulate metabolism and stress response.

Buccal pigmentation: This is not a typical feature of AN.

Raised gonadotrophin levels: Gonadotrophin levels are usually reduced in AN, leading to amenorrhoea in women and loss of sexual interest in men.

Hyperkalaemia: AN patients may have high levels of potassium in their blood.

Diagnostic criteria: According to the ICD-10, a definite diagnosis of AN requires body weight maintained at least 15% below the expected, self-induced weight loss, body image distortion, endocrine disorder involving the hypothalamic–pituitary–gonadal axis, and delayed or arrested pubertal events if onset is prepubertal.

Understanding Anorexia Nervosa: Features and Diagnostic Criteria